Navigation Links
Vermillion Reports Results for Third Quarter 2011
Date:11/9/2011

ter of 2011 totaled $114,000, as compared to $299,000 in the same year-ago quarter related to the company's past achievement of certain milestones under the Strategic Alliance Agreement with Quest Diagnostics.

Total operating expenses increased in the third quarter of 2011 to $4.8 million from $4.0 million in the same period a year ago. The increase was due primarily to higher clinical trial and collaboration costs for the ongoing development of the company's ovarian cancer program and VASCLIR as well as an increase in legal fees associated with our Molecular Analytical Systems, Inc. litigation. Operating expenses in the third quarter of 2011 included $0.4 million in non-cash stock-based compensation, as compared to $1.2 million in the same year-ago quarter.

Net loss for the third quarter was $4.7 million or $(0.31) per share, as compared to $2.7 million or $(0.26) per share in the same year-ago quarter. Net loss in the year-ago quarter included $1.0 million in other income resulting from the fair value revaluation of common stock warrants.

Weighted average shares outstanding were 14.8 million in the third quarter of 2011, as compared to 10.5 million weighted average shares outstanding in the same period in 2010.

As of September 30, 2011, the company's cash and cash equivalents totaled $27.2 million. The company used $4.3 million in cash from operations during the third quarter and paid the $5 million principal amount of convertible notes which became due in September. Cash utilization from operations during the fourth quarter is expected to be $4-$5 million.

Management Commentary"Our third quarter results demonstrated on-going progress on several fronts," said Gail Page, the company's president and CEO. "We grew OVA1 sales and highlighted its benefit when used in conjunction with imaging as an aid for physicians in the assessment of adnexal masses. Strategically, we are pleased to announce the agreement to purchase the ovarian
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
2. Vermillion Engages Liolios Group to Lead Investor Relations Program
3. Vermillion Enhances Management Team With A Key Addition
4. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
5. Vermillion Reports Financial Results for the First Quarter 2011
6. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
7. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
8. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
9. Vermillion Announces $21.8 Million Public Offering
10. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
11. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... 2014  Vesselon, Inc. today announced the appointment of ... September 15, 2014. Dr. Raths, appointment follows Vesselon,s engagement ... to market a private preferred Series A round to ... "Jurgen,s deep experience across multiple functional areas ... to Vesselon as we develop our device that can ...
(Date:9/23/2014)... 23, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... (NOL) from Health Canada to begin clinical trials ... lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).  ... acute moderate to moderately severe pain. The Health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... 7 Genomic Health,Inc. (Nasdaq: GHDX ) ... the,company,s Oncotype DX(R) breast cancer test are scheduled ... Breast Cancer Symposium, taking place,December 13-16, 2007. Oncotype ... to predict the likelihood of recurrence and the ...
... PROCRIT(R) (Epoetin alfa),studies will be presented at the American Society of ... The data will provide important insights including:, ... limiting the use of erythropoiesis-stimulating agents (ESAs) ... -- the use of PROCRIT in extended dosing regimens; ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 2PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 4PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 5PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 6PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 7PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 8PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 9
(Date:9/23/2014)... The Sloane Clinic™, a leading ... Malaysia providing advanced aesthetic dermatology and cosmetic solutions ... impressive skin care repertoire. Specially formulated with super-powered ... the evil forces of aging, acne and photo ... new addition is revolutionizing the way we treat ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... using cholesterol-lowering drugs while in the hospital for a hemorrhagic ... more than four times more likely to survive than people ... People taking the commonly used drugs known as statins ... or to a rehabilitation facility, the study reports. When ...
(Date:9/23/2014)... Hospital Medical Center have published the first study ... published in The Journal of Allergy and ... systemic disorder that has high levels of eosinophils ... series of allergy-associated-immune mechanisms and has a gene ... of a related disorder, eosinophilic esophagitis (EoE). ...
Breaking Medicine News(10 mins):Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3
... well, sports commentators may describe them as being "hot" or ... the eye of the beholder, but a new study by ... that a streak of positive outcomes is likely to continue., ... the study analyzed five years of NBA free throws that ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- Older ... a greater risk of developing dementia than folks who believe ... the journal Neurology . Someday, "having people rate ... to determine a person,s risk of dementia, especially for people ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
... Oct. 5 (HealthDay News) -- The percentage of nursing ... flu shot is lower than the national goal, and the ... study finds. Brown University researchers examined annual patient records ... 2006-07 to 2008-09. The overall flu vaccination rate for ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Nearly one in ... center than 10 years ago due to closures of hospital ... had the greatest impact on black people, the poor, the ... San Francisco researchers. "Trauma centers aren,t just for ,certain, ...
... life experiences -- the ups and downs, and everything in ... emotional set point as adults, according to a new study ... suggests that, in addition to our genes, our life experiences ... "In this time of emphasis on genes for this ...
Cached Medicine News:Health News:Athletes' winning streaks may not be all in our -- or their -- heads 2Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:Nursing Homes Not Meeting Flu-Shot Goals, Study Says 2Health News:More Americans Face Longers Trips to ER 2Health News:Virginia Commonwealth University study: We are what we experience 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: